Dr. James Davis is a practicing physician of Internal Medicine, and serves as the Medical Director for Duke Center for Smoking Cessation, Director of the Duke Smoking Cessation Program and Co-Director of the Duke-UNC Tobacco Treatment Specialist Credentialing Program. His research focuses on development of new pharmaceutical treatments for smoking cessation. He is principal investigator on several trials including a study on “adaptive” smoking cessation and several trials on new medications for smoking cessation. The new medications leverage more novel neurobiological mechanisms - NMDA receptor antagonism, nicotinic receptor antagonism, which impact addiction-based learning and cue response. Additionally, Dr. Davis serves as co-investigator on trials on lung cancer screening, e-cigarettes, minor nicotine alkaloids, imaging trials, lung function trials and others. Dr. Davis leads the Duke Smoke-Free Policy Initiative, is co-author on a national tobacco dependence treatment guideline, and provides training in tobacco dependence treatment for the Duke School of Medicine, Duke Internal Medicine, Family Practice and Psychiatry residency programs.
Education and Training
- Internal Medicine Residency, Mayo Clinic, 1997 - 2000
- M.D., Southern Illinois University School of Medicine, 1997
- Pfizer Preceptorship
- A Randomized, Double-Blind Study to Evaluate the Impact of AXS-05 on Smoking Behavior.
- Lung Cancer Screening Implementation: Evaluation of Patient-Centered Care
- Duke Cancer Institute Application for Administrative Supplement for the P30 Cancer Center Support Grant to Develop Tobacco Cessation Treatment Capacity and Infrastructure for Cancer Patients
- The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence